Other antibodies have failed where hospitals need them most
As vaccines began their hopeful march across a weary world in December 2020, science turned its gaze toward those already fallen — the hospitalized, the severely ill, the ones prevention had not reached in time. Vir Biotechnology and GlaxoSmithKline advanced their experimental antibody treatment VIR-7831 into Phase 3 trials, targeting a gap that had quietly widened throughout the pandemic: the absence of proven therapies for patients already in crisis. In a moment when the tools of prevention shone brightly, this effort asked a harder question — what do we owe those for whom prevention came too late?
- With only one FDA-approved COVID-19 treatment on the market — and the WHO casting doubt on even that — hospitalized patients in late 2020 had alarmingly few options beyond supportive care.
- VIR-7831 enters the field with a dual mechanism: neutralizing the virus while simultaneously destroying already-infected cells, a combination its developers believe could succeed where other antibodies have repeatedly failed in hospital settings.
- The trial is operating under the NIH's accelerated COVID-19 therapeutic program, signaling institutional urgency and a coordinated push to compress the timeline from promise to proof.
- Markets responded with cautious optimism — Vir shares ticked up in premarket trading — but the real verdict will come from the bodies of critically ill patients enrolled in wards where the pandemic's weight is felt most acutely.
In December 2020, even as vaccines rolled out with extraordinary efficacy, Vir Biotechnology and GlaxoSmithKline announced they had begun enrolling patients in a Phase 3 trial for VIR-7831, an experimental antibody treatment aimed at those already hospitalized with COVID-19. The trial was running under the NIH's accelerated therapeutics program, designed to fast-track the most promising candidates through the pipeline.
The drug's design set it apart from prior attempts: rather than simply neutralizing the virus, VIR-7831 also targets and destroys cells already infected — a dual approach that GSK's chief scientific officer believed could work where other antibodies had fallen short in hospital settings. That distinction mattered, because the therapeutic landscape was nearly bare. Gilead's Veklury remained the only FDA-approved COVID-19 treatment, and the WHO had recently recommended against its use, leaving physicians with little to offer their most critical patients.
The contrast with the vaccine story was sharp. Pfizer and Moderna had reported efficacy rates near 95%, offering genuine hope for prevention. But for those already in intensive care units, hope required something different — a treatment, not a shield. VIR-7831 was an attempt to answer that need.
Vir's stock rose modestly on the news, a small market signal amid a year in which the company's shares had climbed nearly 159%. Phase 3 trials — the final major threshold before regulatory approval — would now determine whether this antibody could become a real option for the patients medicine had not yet found a way to save.
On a December morning in 2020, with vaccines rolling out across the country and showing remarkable promise, two pharmaceutical companies announced they were moving forward with a different kind of weapon against COVID-19. Vir Biotechnology and GlaxoSmithKline had begun enrolling patients in a Phase 3 clinical trial for an experimental antibody treatment called VIR-7831, marking a significant step in the race to develop drugs that could help people already sick enough to be hospitalized.
The trial was being conducted under the umbrella of the National Institutes of Health's Accelerating COVID-19 Therapeutic Interventions and Vaccines Program, a coordinated effort to fast-track promising treatments. The companies were specifically testing VIR-7831 in hospitalized COVID-19 patients—the sickest of the sick, people for whom prevention had already failed. The drug works by doing two things at once: it neutralizes the virus itself and kills cells that have already been infected, a dual mechanism that GSK's chief scientific officer, Dr. Hal Barron, suggested could work where other antibody treatments had not. In hospital settings, where patients were already severely ill, other antibodies had largely failed to show meaningful benefit. This treatment, the companies hoped, might be different.
The announcement came at a moment of stark contrast in the pandemic response. Vaccines—Pfizer and Moderna's shots among them—had demonstrated efficacy rates around 95% in clinical trials, a stunning success that offered genuine hope for prevention. But the therapeutic side of the equation had lagged considerably. Only one drug, Gilead Sciences' Veklury, had won FDA approval as a COVID-19 treatment, and even that approval came with complications. The World Health Organization had recently recommended against using Veklury, raising questions about whether it actually helped patients or merely seemed to. Into this gap stepped VIR-7831, an attempt to give doctors something more to offer the people already in their intensive care units.
The stock market took notice. Vir's shares rose 1.3% in premarket trading the day after the announcement, a modest but measurable vote of confidence. By year's end, Vir's stock would be up 158.9% for the year, while GSK's shares had fallen 21.4% over the same period. The broader market, represented by the S&P 500, had gained 15.2%.
Phase 3 trials are the final major hurdle before a drug can be approved for widespread use. They involve hundreds or sometimes thousands of patients and are designed to confirm that a treatment works and is safe enough for the general population. For a hospitalized COVID-19 patient in December 2020, enrollment in such a trial represented one of the few remaining options beyond supportive care. The companies were betting that VIR-7831 could fill a genuine void—not preventing infection, like the vaccines, but actually treating people whose bodies were already fighting a losing battle against the virus.
Notable Quotes
This treatment has the potential to neutralize the virus and kill infected cells, which could allow it to be effective for patients in hospital settings, where other antibodies have so far not shown an impact.— Dr. Hal Barron, GSK chief scientific officer
The Hearth Conversation Another angle on the story
Why does it matter that this is an antibody treatment specifically, rather than some other kind of drug?
Antibodies are like precision-guided missiles. They're designed to recognize and attack specific parts of the virus. In theory, they can work quickly in people who are already very sick, whereas other drugs might take time to build up in the system.
But the source mentions that other antibodies haven't worked well in hospitals. What's different about this one?
That's the gamble. VIR-7831 is supposed to do two things—neutralize the virus and kill infected cells. The companies are arguing that combination approach is what's been missing. Whether it actually works is what Phase 3 will tell us.
The vaccines are 95% effective. Why would anyone need a treatment if prevention works that well?
Because not everyone gets vaccinated, and vaccines take time to work. In December 2020, vaccines were just rolling out. There were thousands of people already in hospitals, and they needed help now, not prevention for next time.
What does it say that the WHO questioned the one approved treatment?
It says the field is still figuring this out. Veklury was approved, but there's real debate about whether it actually saves lives. That uncertainty is why a new approach matters—even if it's unproven, it's a different bet.
Who benefits if this works?
Hospitalized patients, obviously. But also the companies—Vir's stock was already up 158% that year. And the broader medical system, which has very few tools for treating severe COVID-19.